Nukkleus Inc. Relocates HQ to Jersey City, NJ

TL;DR

**Nukkleus Inc. moved its main office to Jersey City, NJ, from Shanghai.**

AI Summary

Nukkleus Inc. filed an 8-K on January 17, 2024, to update its principal executive offices from Shanghai, China, to 525 Washington Blvd., Jersey City, New Jersey 07310. This change signifies a shift in the company's operational base, potentially indicating a strategic move to consolidate operations or enhance accessibility within the U.S. This matters to investors as a physical relocation can impact operational efficiency, regulatory oversight, and market perception, potentially influencing future stock performance.

Why It Matters

This relocation could streamline operations and improve access to U.S. financial markets and talent, potentially boosting investor confidence and operational efficiency.

Risk Assessment

Risk Level: low — A change in business address is generally a low-risk event, primarily administrative, with potential minor operational impacts.

Analyst Insight

Investors should monitor future filings for any strategic shifts or operational updates that might follow this relocation, as it could signal broader changes in the company's focus or market strategy.

Key Numbers

• $0.0001 — Par Value Per Share (The par value of Nukkleus Inc.'s Common Stock.)
• 212-791-4663 — Registrant's Telephone Number (The primary contact number for Nukkleus Inc.)

Key Players & Entities

• Nukkleus Inc. (company) — the registrant filing the 8-K
• 525 Washington Blvd. Jersey City, New Jersey 07310 (address) — new principal executive offices
• 99 DAN BA ROAD C-9 PUTUO DISTRICT SHANGHAI 200062 (address) — former business address
• January 17, 2024 (date) — date of earliest event reported and filing date
• $0.0001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Nukkleus Inc. will experience increased operational efficiency due to its new U.S. location. (Nukkleus Inc.) — medium confidence, target: 2025-01-17
• The company may attract more U.S.-based talent following the relocation. (Nukkleus Inc.) — medium confidence, target: 2024-07-17

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NUKK The Nasdaq
• $11.50 — sable for one Share of Common Stock for $11.50 per share NUKKW The Nasdaq Stock Ma

Filing Documents

• ea191679-8k_nukkleus.htm (8-K) — 30KB
• ea191679ex99-1_nukkleus.htm (EX-99.1) — 12KB
• 0001213900-24-003915.txt ( ) — 263KB
• nukk-20240117.xsd (EX-101.SCH) — 4KB
• nukk-20240117_def.xml (EX-101.DEF) — 27KB
• nukk-20240117_lab.xml (EX-101.LAB) — 37KB
• nukk-20240117_pre.xml (EX-101.PRE) — 25KB
• ea191679-8k_nukkleus_htm.xml (XML) — 5KB

01. Changes in Registrant's Certifying Accountant

Item 8.01. Changes in Registrant's Certifying Accountant. On January 17, 2024, Nukkleus Inc. (the "Company") issued a press release to announce the signing of a Memorandum of Understanding (MOU), that contemplates a substantial increase in Nukkleus' holdings in Jacobi Asset Management. A copy of the press release, dated January 17, 2024, is included as Exhibit 99.1 to this report.

01. Exhibits

Item 9.01. Exhibits The exhibits filed or furnished with this report are listed in the following Exhibit Index: Exhibit No. Description 99.1 Press Release dated January 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nukkleus Inc. (Registrant) Dated: January 17, 2024 By: /s/ Emil Assentato Name: Emil Assentato Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR